OPRX OptimizeRx Corp

OptimizeRx to Participate in Upcoming Investor Conferences

OptimizeRx to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: 

  • Barclays 26th Annual Global Healthcare Conference, Miami Beach, March 13th, 2024
  • 36th Annual ROTH Conference, Dana Point, March 17th – March 19th, 2024

Management will be participating in a fireside chat and will be holding one-on-one meetings with investors. To request a meeting or for more details about the conferences please reach out to your institutional contacts.

Conference Details: 

Barclays 26th Annual Global Healthcare Conference
Date: Wednesday, March 13th
Format:Fireside Chat & 1x1 Meetings
Location:The Loews Miami Beach Hotel

   

36th Annual ROTH Conference
Date: March 17th – March 19th
Format:Fireside Chat & 1x1 Meetings
Location:The Ritz Carlton Laguna Niguel
  

About OptimizeRx 

OptimizeRx provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 2 million U.S. healthcare providers and millions of their patients through an intelligent technology platform embedded within a proprietary digital point-of-care network, as well as mass digital communication channels, OptimizeRx helps life sciences organizations engage and support their customers. 

For more information, follow the Company on ,  or visit .  

Important Cautions Regarding Forward Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans, and future performance. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.  

OptimizeRx Contact  

Andy D’Silva, SVP Corporate Finance 

 

Media Relations Contact  

Dilma Bennett, Media Relations Manager 

 

Investor Relations Contact 

Ashley Robinson 

LifeSci Advisors, LLC 

 



EN
21/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OptimizeRx Corp

 PRESS RELEASE

OptimizeRx Provides Business Update and Sets First Quarter 2024 Confer...

OptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET 1Q24 revenue expected to grow over 40% year-over-year and come in between $18.5 - $19.2 million First quarter revenue and adjusted EBITDA to come in ahead of consensus DAAP adoption and cross selling activities are tracking ahead of internal expectations WALTHAM, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) an...

 PRESS RELEASE

OptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) R...

OptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) Report WALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2024. As a company that provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures t...

 PRESS RELEASE

OptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial ...

OptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial Results Q4 revenue of $28.4 million, increasing 44% year-over-yearQ4 gross profit increased 43% year-over-year to $17.8 million with gross margins coming in at 63% for both periodsAcquired Healthy Offers, Inc. (dba Medicx Health), a leading healthcare consumer-focused omnichannel marketing and analytics company that significantly expands our footprint with consumers and patientsMeaningfully increased our DAAP footprint: 24 DAAP deals in 2023 compared to six deals in 2022 WALTHAM, Mass., April 16, 2024 (GLOBE NE...

 PRESS RELEASE

OptimizeRx Named America’s Fastest-Growing Company for Fifth Year in a...

OptimizeRx Named America’s Fastest-Growing Company for Fifth Year in a Row Market Embraces Disruptive AI-Powered Capabilities WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has secured a coveted spot on the 2024 Financial Times’ Americas’ Fastest-Growing Companies list for a remarkable fifth consecutive year, ranking at 253. The Americas’ Fastest Growing Companies 2024 ranking identifies companies with...

 PRESS RELEASE

OptimizeRx Sets Fourth Quarter 2023 Conference Call for March 28, 2024...

OptimizeRx Sets Fourth Quarter 2023 Conference Call for March 28, 2024 at 8:30 a.m. ET WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, March 28, 2024, at 8:30 a.m. Eastern Time to discuss the preliminary, unaudited results for the fourth quarter. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch